Homegrown pharma major Cipla Ltd on Monday said the Directorate of Revenue Intelligence , Mumbai Zonal Unit, conducted search proceedings at its office in Vikhroli, Mumbai, and depot in Bhiwandi, Thane, Maharashtra, in connection with the classification and exemption of an imported pharmaceutical finished product."...we hereby notify that the Directorate of Revenue Intelligence, Mumbai zonal unit, on 16 November 2026 conducted a search proceeding at the Company’s office located in Vikhroli, Mumbai, Maharashtra and at its depot located in Bhiwandi, Thane, Maharashtra.
The Company extended its full co-operation and assistance in this regard," according to a stock exchange filing. The search was initiated and concluded on November 16 under Section 105 of the Customs Act, 1962, the pharmaceutical company said. The company added that the search would have no material impact on its financials, operations or other activities.
Second Quarter ResultsCipla's net profit declined 35% year-on-year to ₹878 crore, falling short of the CNBC-TV18 poll estimate of ₹949 crore. The decline was attributed to lower other income and higher expenses. Revenue for the quarter fell 2.4% from a year earlier to ₹7,404 crore, compared with the Street estimate of ₹7,498 crore.
Earnings before interest, tax, depreciation and amortisation declined 26.7% year-on-year to ₹1,388 crore from ₹1,894.75 crore in the corresponding quarter last year. However, the figure was marginally ahead of the CNBC-TV18 poll estimate of ₹1,371 crore.oALSO READ | Deven Choksey prefers Sun Pharma, Cipla for fresh buying; sees upside in Indian ITCipla’s EBITDA margin contracted 630 basis points year-on-year to 18.7%, from 25% in the year-ago quarter.
The margin, however, was above the CNBC-TV18 poll estimate of 18.3%. Cipla's One-India business reported its highest-ever quarterly sales, growing 12% year-on-year. In North America, quarterly revenue stood at $172 million. The company said it expects performance in the region to remain supported by its upcoming product pipeline.
In South Africa, Cipla's private-market business grew approximately 1.3 times faster than the market. Its Emerging Markets and Europe business reported quarterly revenue of $101 million, despite geopolitical uncertainties. The spending was directed largely towards product filings and key development programmes.
Cipla reported a net cash position of ₹9,823 crore. Its debt primarily comprises lease liabilities and working capital requirements. Shares of Cipla Ltd ended at ₹1,394.00, down by ₹1.00, or 0.072%, on the BSE.
